FU
FUP.F Fuji Pharma Co. Ltd
- Market cap
- EUR 274M
- P/E
- 15.4x
- P/B
- 0.95x
- ROE
- 4.7%
- Dividend yield
- 2.62%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is FUP.F undervalued?
Graham numberFUP.F trades 19.4% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Fuji Pharma Co. Ltd fundamental analysis
No fundamental analysis for Fuji Pharma Co. Ltd yet.
Fuji Pharma Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Fuji Pharma Co. Ltd
Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women, in vitro diagnostics, acute medical care products, and curative medicines, and information regarding pharmaceuticals and health services, as well as contract manufacturing services. Fuji Ph…
Full company profileFuji Pharma Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Fuji Pharma Co. Ltd annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 34.2B | 35.4B | 37.9B | 36.3B | 33.8B | 34.0B | 35.4B | 40.9B | 46.1B | 51.7B | 60.5B |
| Gross Profit | 13.5B | 14.7B | 16.0B | 15.8B | 14.9B | 14.8B | 14.6B | 16.5B | 17.8B | 20.8B | 23.6B |
| Operating Income | 3.57B | 4.32B | 4.40B | 4.18B | 3.14B | 3.35B | 3.78B | 3.86B | 3.88B | 4.99B | 7.19B |
| EBITDA | - | 6.59B | 6.76B | 6.13B | 5.01B | 5.53B | 6.55B | 7.53B | 12.2B | 8.30B | 3.20B |
| Net Income | 2.12B | 3.30B | 3.37B | 2.96B | 2.09B | 2.43B | 2.70B | 3.44B | 6.15B | 3.00B | 2.43B |
| EPS | - | 110 | 113 | 95 | 67 | 100 | 111 | 141 | 253 | 123 | 93 |
| Balance Sheet | |||||||||||
| Total Assets | 48.1B | 49.6B | 53.1B | 60.7B | 62.0B | 64.2B | 75.5B | 85.3B | 90.0B | 93.4B | 98.4B |
| Total Liabilities | 18.9B | 17.0B | 17.8B | 21.4B | 22.0B | 31.6B | 39.7B | 44.2B | 44.4B | 46.5B | 46.5B |
| Shareholders' Equity | 29.2B | 32.6B | 35.3B | 39.4B | 40.0B | 32.7B | 35.8B | 41.2B | 45.6B | 46.9B | 51.9B |
| Cash & Short-term Investments | 6.82B | 5.50B | 6.25B | 8.49B | 12.0B | 10.2B | 3.55B | 2.32B | 4.59B | 7.25B | 9.95B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 4.51B | 3.24B | 3.77B | 7.04B | 5.77B | 5.99B | -658M | 1.92B | 4.15B | 5.80B | - |
| Capital Expenditure | 2.65B | 1.48B | 1.45B | 1.70B | 2.32B | 3.79B | 5.10B | 3.90B | 4.37B | 3.85B | 0.00 |
| Free Cash Flow | - | 1.70B | 2.14B | 3.75B | 3.16B | 2.10B | -13.1B | -1.98B | -221M | 1.95B | - |
| Ratios | |||||||||||
| ROE | 7.2% | 10.1% | 9.5% | 7.5% | 5.2% | 7.4% | 7.5% | 8.3% | 13.5% | 6.4% | 4.7% |
| ROA | 4.4% | 6.7% | 6.3% | 4.9% | 3.4% | 3.8% | 3.6% | 4.0% | 6.8% | 3.2% | 2.5% |
| Net Profit Margin | 6.2% | 9.3% | 8.9% | 8.2% | 6.2% | 7.2% | 7.6% | 8.4% | 13.3% | 5.8% | 4.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Fuji Pharma Co. Ltd dividends
- Dividend yield
- 2.62%
- Forward dividend
- 0.27 EUR
- Payout ratio
- 34.5%
- Ex-dividend date
- Sep 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | JPY 1.04B | 42 | 34.5% |
| 2024 | JPY 972M | 40 | 15.8% |
| 2023 | JPY 899M | 37 | 26.2% |
| 2022 | JPY 729M | 30 | 27.0% |
| 2021 | JPY 807M | 33 | 33.2% |
| 2020 | EUR 904M | 29 | 43.4% |
| 2019 | EUR 839M | 27 | 28.3% |
| 2018 | EUR 794M | 27 | 23.5% |
| 2017 | EUR 704M | 24 | 21.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Jun 27, 2018.
Who owns Fuji Pharma Co. Ltd
- Insiders 41.09%
- Institutions 14.97%
- Public & others 43.94%
- Shares outstanding 26.1M
- Free float 14.4M
Fuji Pharma Co. Ltd company profile
- Company name
- Fuji Pharma Co. Ltd
- Ticker
- FUP.F
- ISIN
- JP3816200004
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,760
- Fiscal year end
- September
- Address
- 5-7 Sanban-cho, Tokyo, Japan, 102-0075
- Phone
- 81 3 3556 3344
- Website
- fujipharma.jp
About Fuji Pharma Co. Ltd
Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women, in vitro diagnostics, acute medical care products, and curative medicines, and information regarding pharmaceuticals and health services, as well as contract manufacturing services. Fuji Pharma Co., Ltd. was incorporated in 1965 and is headquartered in Tokyo, Japan.
Fuji Pharma Co. Ltd management
6- Mr. Shuhei MoritaPresident, CEO & Director · born 1974
- Mr. Toyoyuki KamideExecutive VP, Head of Corporate Management & Director · born 1965
- Mr. Atsuya MitsuhashiManaging Executive Officer & Corporate Planning Department · born 1971
- Masayuki NaganawaManaging Executive Officer & Head of Research and Development
- Mr. Satoshi SuzukiExecutive VP, Head of Business Strategy Division & Director · born 1963
- Hitoshi YokoyamaExecutive Officer & Head of Pharmaceutical Business Division